Drive DeVilbiss names new CEO
Drive DeVilbiss Healthcare earlier this week named Bob Gilligan to its CEO post. Gilligan comes to Drive from GE Industrial Solutions where he served in the same capacity.
With the appointment, Harvey Diamond assumes the role of vice chairman for the Port Washington, N.Y.-based company, where he will serve as a senior advisor.
Diamond will continue to serve on Drive's board of directors.
Gilligan brings with him more than 30 years of experince in both manufacturing and service businesses. In his last role, he successfully led the transformation of GE's $3.6 billion global business.
Gilligan is a graduate of Bucknell University with a BS in Mechanical Engineering and an MBA from the University of Pennsylvania Wharton School.
He is currently a member of the board of trustees for Bucknell University.
CVS Pharmacy brings same-day prescription delivery to Manhattan
Manhattanites can now get their prescriptions without leaving their apartments. CVS Pharmacy has introduced same-day prescription delivery in the New York City borough, which the company said it’s offering free of charge and is part of a larger push for prescription delivery across the country.
“Free, same-day prescription delivery gives customers the option of having the pharmacy they trust deliver right to them at their homes or work in Manhattan,” CVS Health executive vice president and CVS Pharmacy president Helena Foulkes said. “Delivery is another way that we can meet our customers wherever, however and whenever they want in order to make healthcare easier.”
All of the Woonsocket, R.I.-based company’s Manhattan locations started offering delivery service this week, which CVS Pharmacy said includes prescriptions and OTC products delivered in tamper-proof packaging. Orders placed by 11 a.m. are delivered by 4 p.m. and orders placed by 4 p.m. are delivered by 8 p.m., the company said.
As part of its launch, CVS Pharmacy decked out the exterior of Penn Station Plaza and the Columbus Circle subway station with advertising highlighting the delivery offering. The company has launched a website with more information about the offering, as well as a delivery concierge service line at 1-833-CVS-2YOU.
“Our goal is to reach people living and working in Manhattan to let them know about our new prescription delivery service through a fun, highly visible campaign that will reach them while they are traveling around the city as well as through digital and mobile channels,” said Norman de Greve, CVS Health senior vice president and chief marketing officer.
CVS Pharmacy’s Manhattan delivery offerings are the first to roll out of its various planned delivery offerings that it announced alongside its third-quarter earnings. Miami, Boston, Philadelphia, San Francisco and Washington, D.C. are slated to see same-day delivery services in early 2018. Other markets nationwide will see next-day delivery next year as well, the company said.
The launch of the delivery services comes days after CVS Pharmacy parent company CVS Health agreed to acquire health insurer Aetna for $69 billion. The companies' CEOs have said that CVS Pharmacy’s locations and services offerings will play a key role in the combined company if the deal is approved.
Moberg Pharma to focus on North America expansion with latest executive promotion
Moberg Pharma last week named Jeff Vernimb VP global consumer health as the company reorganizes its sales and marketing operations to reflect the company's increased focus on the North American market.
Prior to the promotion, Vernimb served as general manager North America.
Direct sales currently account for 90% of the company's total revenue. Under Vernimb's management, North American sales have more than doubled in the past three years to $46 million.
Coordinating management of the commercial consumer health operations on a global basis enables more direct sharing of consumer insights and market learning, the company noted.
Moberg Pharma is currently working toward brining to market its MOB-015 product, which is currently in phase 3 studies. MOB-015 is an internally developed topical formulation of terbinafine building on Moberg Pharma’s experience from its leading OTC product Kerasal Nail/Emtrix.
Oral terbinafine is the gold standard for treating onychomycosis, which impacts approximately 10% of the population, but associated with safety issues including drug interactions and liver damage. For many years, developing a topical terbinafine treatment without the safety issues of oral terbinafine has been highly desirable, but unsuccessful due to insufficient delivery of the active substance through the nail.
The global market opportunity is significant with more than hundred million patients worldwide and a clear need for better products. Moberg Pharma estimates the peak sales potential for MOB-015 to be in the range of $250 million to $500 million.